Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models

With 5-year survival rates below 5%, small cell lung carcinoma (SCLC) has very poor prognosis and requires improved therapies. Despite an excellent overall response to first-line therapy, relapses are frequent and further treatments are disappointing. The goal of the study was to improve second-line...

Descripción completa

Detalles Bibliográficos
Autores principales: Hubaux, Roland, Vandermeers, Fabian, Cosse, Jean-Philippe, Crisanti, Cecilia, Kapoor, Veena, Albelda, Steven M., Mascaux, Céline, Delvenne, Philippe, Hubert, Pascale, Willems, Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005116/
https://www.ncbi.nlm.nih.gov/pubmed/27730151
http://dx.doi.org/10.1183/23120541.00028-2015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005116/
https://www.ncbi.nlm.nih.gov/pubmed/27730151
http://dx.doi.org/10.1183/23120541.00028-2015

Ejemplares similares